TICKERNERD
Menu
COAGHealthcare · Biotechnology

COAG Stock Forecast: Hemab Therapeutics Holdings, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$31
+7.63% on the day

The 5 Wall Street analysts covering Hemab Therapeutics Holdings, Inc. hold a median 12-month price target of $60 — +94.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.3B
Ticker Nerd rank
1 / 100
Median analyst target
$60
Analysts covering
5
Revenue$0.0
Operating income−$26.1M
Net income−$24.1M
Free cash flow−$22.7M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
−30.7%
From high
−43.8%
From low
+23.7%
$25
$55
Range since 1 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

COAG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Hemab Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
39
Revisions
30
Value
15
Issuance
14
Growth
8
Accruals
8
Momentum
7
Quality
5
Volatility
4

Size (39): Smaller than most of the companies we track.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COAG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COAG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 1 May 2026Adjusted close, US dollars
$20$30$40$50$60$70May 26Jun 26Jul 26Aug 26Sep 26Oct 26COAGHigh $65Median $60Low $58

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $58Median $60High $65

The green dot is the last close — the median target sits +94.2% from it.

Recent analyst actionsNewest first

Of the 15 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
12 Aug 2026WedbushMaintainsOutperform$55 → $64
11 Aug 2026HC Wainwright & Co.MaintainsBuy—
11 Aug 2026HC Wainwright & Co.MaintainsBuy$52 → $60
13 July 2026HC Wainwright & Co.MaintainsBuy$40 → $52
13 July 2026HC Wainwright & Co.MaintainsBuy—
13 July 2026JefferiesMaintainsBuy$39 → $47
13 July 2026JefferiesMaintainsBuy—
13 July 2026WedbushMaintainsOutperform—
13 July 2026WedbushMaintainsOutperform$42 → $55
26 June 2026HC Wainwright & Co.ReiteratesBuy—
17 June 2026HC Wainwright & Co.InitiatesBuy—
26 May 2026Evercore ISI GroupInitiatesOutperform—
26 May 2026Goldman SachsInitiatesBuy—
26 May 2026JefferiesInitiatesBuy—
26 May 2026WedbushInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COAG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

COAG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

COAG vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160May 26Jun 26Jul 26Aug 26Sep 26Oct 26COAGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COAG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Hemab Therapeutics Holdings, Inc. (COAG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.3×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
3.0×

Cheaper than 32% of US stocks

EV / EBITDA
−10.2×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
36.2%

Higher than 90% of US stocks

Return on assets
−32.8%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Hemab Therapeutics Holdings, Inc. (COAG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Hemab Therapeutics Holdings, Inc. has a market value of $1.3B and an enterprise value of $884.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$74.4M.

  • Diluted earnings per share, trailing twelve months: $−17.94.

  • Free cash flow in the twelve months to 30 June 2026: −$72.7M.

  • Shares outstanding: 46.7M.

  • Trailing P/E: −12.3×; forward P/E: −11.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Hemab Therapeutics Holdings, Inc. employs 59 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

COAG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
COAGHemab Therapeutics Holdings, Inc.$1.3B
1
RAPPRapport Therapeutics, Inc.$1.4B
39
MAZEMaze Therapeutics, Inc.$1.4B
26
SNDXSyndax Pharmaceuticals, Inc.$1.5B
59
TSHATaysha Gene Therapies, Inc.$1.4B
37
GHRSGH Research PLC$1.4B
62
STOKStoke Therapeutics, Inc.$1.5B
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Hemab Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COAG news & analysis

Hemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung Ladder

Seeking Alpha · 29 Sept 2026positive

Hemab Therapeutics is developing a hemostasis pipeline spanning ultra-rare to mass-market bleeding disorders, with a cash runway into 2029. Its lead asset, sutacimig, showed roughly 84% bleed reduction at low weekly doses in GT with manageable safety, with Phase 3 planned for the second half of 2026, while VWD and heavy menstrual bleeding programs offer additional upside.

Why it matters — COAG watchers would track this because sutacimig's strong Phase 3-ready data and multi-program pipeline could broaden value beyond what the current valuation reflects.

Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

GlobeNewsWire · 24 Sept 2026positive

Hemab Therapeutics announced the appointment of Keli Walbert to its Board of Directors. Walbert brings two decades of commercial leadership and a proven record of successful product launches to the board.

Why it matters — A COAG watcher would care because adding an executive with extensive commercial and launch expertise to the board could strengthen the company's ability to bring its therapies to market.

Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

GlobeNewsWire · 17 Sept 2026neutral

Hemab Therapeutics announced that the first participant has been dosed in a Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding. The announcement notes that heavy menstrual bleeding affects roughly 1 in 3 reproductive-aged women, with about 23 million seeking care in the U.S. last year.

Why it matters — This marks the start of clinical testing for a Hemab pipeline candidate addressing a condition that affects a large number of women, offering COAG watchers an early signal on the company's product development progress.

FAQ

Frequently asked questions about COAG stock

What is the COAG stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Hemab Therapeutics Holdings, Inc. have a median 12-month price target of $60, with estimates ranging from $58 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COAG stock a buy right now?

Of the 5 analysts covering Hemab Therapeutics Holdings, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hemab Therapeutics Holdings, Inc. 1 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COAG?

As at 8 Oct 2026, Hemab Therapeutics Holdings, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (39 of 100).

Will COAG stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +94.2% from the last close, and Ticker Nerd's factor model ranks Hemab Therapeutics Holdings, Inc. 1 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COAG stock forecast for 2030?

No analyst covering Hemab Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COAG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $58 to $65 over the next 12 months.

What does Hemab Therapeutics Holdings, Inc. do?

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders.

What is the latest news on COAG?

The most recent item we track (Seeking Alpha, 29 Sept 2026): "Hemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung Ladder". Hemab Therapeutics is developing a hemostasis pipeline spanning ultra-rare to mass-market bleeding disorders, with a cash runway into 2029. Its lead asset, sutacimig, showed roughly 84% bleed reduction at low weekly doses in GT with manageable safety, with Phase 3 planned for the second half of 2026, while VWD and heavy menstrual bleeding programs offer additional upside.

Company

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. Hemab Therapeutics Holdings, Inc. is advancing a pipeline of treatments designed to address serious inherited bleeding conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its lead programs include sutacimig (HMB-001), a bispecific antibody, and HMB-002, a monovalent antibody, both being studied in clinical development for prophylactic use. The company’s work centers on bleeding and coagulation biology, with an emphasis on therapeutic approaches that target underlying disease mechanisms rather than symptom management. Hemab Therapeutics Holdings, Inc. operates as a research-driven biotechnology business serving the rare disease and hematology markets.

CEO Dr. Benny Sorensen M.D., Ph.D. · 59 employees · United States · https://www.hemab.com